GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have a strong overall safety profile backed by large clinical trials involving tens of thousands of patients. They carry real side effects, mostly gastrointestinal, and a few serious risks worth understanding. But for most people, the benefits significantly outweigh the downsides.
Digestive Side Effects Are the Most Common
The side effect you’re most likely to experience is nausea. Across clinical trials, about 21% of people taking a GLP-1 medication report it. Diarrhea affects roughly 11%, vomiting about 9%, and constipation around 8%. These numbers vary by specific drug. Semaglutide causes nausea in about 21.5% of users, while tirzepatide hits around 25%. Dulaglutide tends to be gentlest on the stomach, with nausea rates near 10%.
These side effects are usually worst during the first few weeks or after a dose increase, then taper off as your body adjusts. The slow dose-escalation schedules that most prescribers follow exist specifically to minimize this adjustment period. For most people, the nausea is manageable and temporary, not a reason to stop treatment.
Stomach Paralysis: Rare but Real
GLP-1 medications work partly by slowing how fast your stomach empties, which helps you feel full longer. In rare cases, this effect goes too far, leading to gastroparesis, where the stomach essentially stops moving food through on schedule. Symptoms include severe bloating, persistent nausea, and abdominal pain that goes beyond the typical adjustment period.
The precise prevalence of gastroparesis from these medications is still unknown, but case reports describe it as unusual rather than common. The reassuring part: in documented cases, symptoms typically resolve after stopping the medication. One published case report found complete resolution of nausea within a month of discontinuation. If you already have significant bloating, nausea, or abdominal discomfort before starting treatment, your prescriber may avoid GLP-1 medications to prevent worsening those symptoms.
Thyroid Cancer Concerns
Every GLP-1 medication carries a boxed warning about thyroid tumors. This stems from rodent studies showing that these drugs stimulate the growth of a specific type of thyroid cell (C-cells), leading to tumors in rats and mice at doses comparable to human therapeutic levels. In humans, the picture is less clear. A large database analysis covering more than 6.6 million people found 236 thyroid cancer cases among GLP-1 users, including 64 cases of medullary thyroid cancer, the specific type linked to C-cell growth.
Whether GLP-1 medications directly cause thyroid cancer in humans remains uncertain, but regulators take the signal seriously. If you or a close family member has had medullary thyroid cancer, or if you have a genetic condition called Multiple Endocrine Neoplasia type 2 (MEN2), these medications are generally avoided. Your prescriber will typically ask about thyroid cancer history before writing a prescription.
Cardiovascular Benefits Are Well Documented
One of the strongest safety signals for GLP-1 medications actually runs in the positive direction. The SELECT trial, which followed patients with obesity or overweight and existing heart disease but no diabetes, found that semaglutide reduced the combined risk of cardiovascular death, heart attack, and stroke by 20% compared to placebo (6.5% vs. 8.0%). Nonfatal heart attacks specifically dropped by 28%.
This builds on earlier trials in people with type 2 diabetes showing similar heart benefits. For people with cardiovascular risk factors, these medications do double duty, addressing weight while actively protecting the heart.
Mental Health and Suicidal Thoughts
Early concerns about a possible link between GLP-1 medications and suicidal thoughts prompted the FDA to conduct one of the most thorough reviews in recent memory. The agency analyzed 91 placebo-controlled trials covering nearly 108,000 patients and found no increased risk of suicidal ideation or behavior. A separate real-world study comparing over 2.2 million medication users reached the same conclusion. The FDA also found no elevated rates of depression, anxiety, irritability, or psychosis.
Based on this evidence, the FDA in 2025 formally requested that manufacturers remove suicidal behavior warnings from labels on Wegovy, Saxenda, and Zepbound. This is as close to a clean bill of health on this question as regulatory science gets.
Muscle Loss During Weight Loss
Any significant weight loss, whether from medication, diet, or surgery, costs some muscle along with fat. With GLP-1 medications, roughly 25% to 40% of the weight you lose comes from lean mass rather than fat. That sounds alarming, but context matters: caloric restriction alone produces similar ratios, with about 30% of weight loss coming from lean tissue. And because you’re losing a larger proportion of fat overall, your body composition (the ratio of muscle to total weight) actually improves.
The practical takeaway is that resistance training matters while you’re on these medications. Lifting weights or doing bodyweight exercises helps preserve muscle during weight loss, regardless of how that weight loss happens. Your prescriber or a physical therapist can help you build an appropriate routine.
Kidney Safety
For people with reduced kidney function, GLP-1 medications appear not just safe but potentially protective. In the SELECT trial, participants with moderate kidney impairment who took semaglutide had 21% fewer serious adverse events than those on placebo. Rates of acute kidney injury were roughly halved (3.5% vs. 6.7%). Gastrointestinal side effects do tend to increase as kidney function decreases, but this happens in both treated and untreated groups at similar rates.
European regulators still advise caution for people with severely reduced kidney function (below a certain filtration threshold), so your prescriber may monitor kidney labs if you have existing kidney disease.
What to Know Before Surgery
Because GLP-1 medications slow stomach emptying, they create a specific risk during anesthesia: food remaining in the stomach can be aspirated into the lungs. The American Society of Anesthesiologists issued guidance recommending that patients on weekly GLP-1 doses (like most semaglutide and tirzepatide formulations) hold their medication for a full week before any elective procedure. If you take a daily formulation, skip it on the day of surgery.
If you didn’t hold the medication as recommended but have no GI symptoms, your anesthesiologist may use an ultrasound to check whether your stomach is empty before proceeding. If you’re experiencing nausea, bloating, or abdominal pain on the day of surgery, the procedure will likely be rescheduled. For emergency surgeries, the medical team treats you as having a full stomach and adjusts their approach accordingly. The key step is telling your surgical team that you’re on a GLP-1 medication well before your procedure date, so they can plan around it.